When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy

[1]  R. Terkeltaub,et al.  Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. , 2022, NEJM evidence.

[2]  P. Tugwell,et al.  Serum Urate as a Proposed Surrogate Outcome Measure in Gout Trials: From the OMERACT Working Group. , 2021, Seminars in Arthritis and Rheumatism.

[3]  M. Hudgens,et al.  Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. , 2021, JAMA.

[4]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[5]  M. Kolber,et al.  Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.

[6]  W. Taylor,et al.  The experience of a gout flare: a meta-synthesis of qualitative studies. , 2020, Seminars in arthritis and rheumatism.

[7]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis & rheumatology.

[8]  M. Doherty,et al.  Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care , 2019, Joint, bone, spine : revue du rhumatisme.

[9]  L. Duley,et al.  Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial , 2018, The Lancet.

[10]  J. Singh,et al.  Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. , 2018, Seminars in arthritis and rheumatism.

[11]  M. Mayes,et al.  Myeloablative Autologous Stem‐Cell Transplantation for Severe Scleroderma , 2018, The New England journal of medicine.

[12]  A. Taniguchi,et al.  Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study , 2017, Annals of the rheumatic diseases.

[13]  A. Worsley,et al.  A Meta-Synthesis of Qualitative Studies Exploring Men’s Sense of Masculinity Post–Prostate Cancer Treatment , 2017, Cancer nursing.

[14]  James M Robins,et al.  Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.

[15]  R. Terkeltaub,et al.  Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) , 2017, Nature Reviews Rheumatology.

[16]  R. McLean.  The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout , 2017, Annals of Internal Medicine.

[17]  T. Mikuls,et al.  To Treat or Not to Treat (to Target) in Gout , 2017, Annals of Internal Medicine.

[18]  A. Qaseem,et al.  Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.

[19]  K. Saag,et al.  Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study) , 2017, Arthritis & rheumatology.

[20]  Hyon K. Choi,et al.  Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy , 2016, Arthritis & rheumatology.

[21]  A. So,et al.  Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study) , 2016, Annals of the rheumatic diseases.

[22]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[23]  J. Lieberman,et al.  A Randomized, Controlled Trial of Total Knee Replacement. , 2016, The New England journal of medicine.

[24]  M. Hernán,et al.  Why post‐progression survival and post‐relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials , 2015, International journal of cancer.

[25]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[26]  James M Robins,et al.  Randomized Trials Analyzed as Observational Studies , 2013, Annals of Internal Medicine.

[27]  G. Yancopoulos,et al.  Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. , 2013, Rheumatology.

[28]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[29]  W. White,et al.  Pegloticase and Chronic Gout—Reply , 2011 .

[30]  P. Lipsky,et al.  Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.

[31]  A. So,et al.  Extended Report , 2022 .

[32]  U. Dafni.  Landmark Analysis at the 25-Year Landmark Point , 2011, Circulation. Cardiovascular quality and outcomes.

[33]  R. Wortmann,et al.  Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. , 2010, Clinical therapeutics.

[34]  J. Singh,et al.  Outcome Domains for Studies of Acute and Chronic Gout , 2009, The Journal of Rheumatology.

[35]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[36]  F. Perez-Ruiz,et al.  Treating to target: a strategy to cure gout. , 2009, Rheumatology.

[37]  P. Macdonald,et al.  Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy , 2008, Nucleosides, nucleotides & nucleic acids.

[38]  H. Schumacher,et al.  The practical management of gout. , 2008, Cleveland Clinic journal of medicine.

[39]  C. Kwoh,et al.  Gout in ambulatory care settings in the United States. , 2008, The Journal of rheumatology.

[40]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[41]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[42]  M. Abel,et al.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.

[43]  G. Hollingworth,et al.  Comparison of injection techniques for shoulder pain: results of a double blind, randomised study. , 1983, British medical journal.

[44]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[45]  A. Gutman,et al.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT. , 1964, The American journal of medicine.

[46]  D. Mccarty,et al.  ACUTE ARTHRITIS IN MAN AND DOG AFTER INTRASYNOVIAL INJECTION OF SODIUM URATE CRYSTALS , 1962 .